Abbott laboratories (ABT)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Net sales

31,904

30,578

27,390

20,853

20,405

20,247

19,657

19,050

21,407

35,166

30,764

29,527

25,914

Cost of products sold, excluding amortization of intangible assets

13,231

12,706

12,409

9,094

8,747

9,218

9,193

8,899

10,017

14,665

13,209

12,612

11,422

Amortization of intangible assets

1,936

2,178

1,975

550

601

555

588

595

884

-

-

-

-

Research and development

2,440

2,300

2,260

1,447

1,405

1,345

1,371

1,461

1,512

3,724

2,743

2,688

2,505

Acquired in-process and collaborations research and development

-

-

-

-

-

-

-

-

-

313

170

97

-

Selling, general and administrative

9,765

9,744

9,182

6,736

6,785

6,530

6,372

6,735

7,365

10,376

8,405

8,435

7,407

Total operating cost and expenses

27,372

26,928

25,826

17,827

17,538

17,648

17,524

17,690

19,778

29,079

24,528

23,833

21,335

Operating earnings

4,532

3,650

1,564

3,026

2,867

2,599

2,133

1,360

1,629

6,087

6,235

5,693

4,578

Interest expense

670

826

904

431

163

150

145

320

359

553

519

528

593

Interest (income)

94

105

124

99

105

77

67

59

65

105

137

201

136

(Income) from the TAP Pharmaceutical Products Inc. joint venture

-

-

-

-

-

-

-

-

-

-

-

118

498

Net foreign exchange (gain) loss

-7

-28

34

-495

93

24

-46

31

20

10

-35

-84

-14

Debt extinguishment costs

-63

-167

-

-

-

-18

-

-1,351

-

-

-

-

-

Other (income) expense, net

191

139

1,413

-786

281

-14

32

1

-119

62

1,375

454

-135

Earnings from continuing operations before taxes

4,077

2,873

2,231

1,413

3,183

2,518

2,041

-220

1,236

5,712

7,193

5,856

4,469

Tax expense (benefit) on earnings from continuing operations

390

539

1,878

350

577

797

53

-457

110

1,086

1,447

1,122

863

Earnings from continuing operations

3,687

2,334

353

1,063

2,606

1,721

1,988

237

1,126

-

-

4,734

3,606

Earnings from discontinued operations, net of tax

-

34

124

337

1,817

563

588

-

-

-

-

-

-

Earnings from Discontinued Operations, net of taxes

-

-

-

321

65

563

-

-

-

-

-

-

-

Earnings (loss) from discontinued operations, net of tax

-

-

-

-

-

-

588

5,726

3,602

-

-

-

-

Gain on sale of Discontinued Operations, net of taxes

-

-

-

16

1,752

-

-

-

-

-

-

146

-

Net Earnings

3,687

2,368

477

1,400

4,423

2,284

2,576

5,963

4,728

4,626

5,745

4,880

3,606

Basic Earnings Per Common Share
Continuing operations (in dollars per share)

2.07

1.32

0.20

0.71

1.73

1.13

1.27

0.15

0.72

-

-

3.06

2.34

Discontinued operations (in dollars per share)

-

0.02

0.07

0.23

1.21

0.37

0.37

3.61

2.31

-

-

0.10

-

Net earnings (in dollars per share)

2.07

1.34

0.27

0.94

2.94

1.50

1.64

3.76

3.03

2.98

3.71

3.16

2.34

Diluted Earnings Per Common Share
Continuing operations (in dollars per share)

2.06

1.31

0.20

0.71

1.72

1.12

1.26

0.15

0.72

-

-

3.03

2.31

Discontinued operations (in dollars per share)

-

0.02

0.07

0.23

1.20

0.37

0.36

3.57

2.29

-

-

0.09

-

Net earnings (in dollars per share)

2.06

1.33

0.27

0.94

2.92

1.49

1.62

3.72

3.01

2.96

3.69

3.12

2.31

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)

1,768

1,758

1,740

1,477

1,496

1,516

1,558

1,575

1,557

1,546

1,546

1,545

1,543

Dilutive Common Stock Options (in shares)

13

12

9

6

10

11

16

17

10

9

8

15

16

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)

1,781

1,770

1,749

1,483

1,506

1,527

1,574

1,592

1,567

1,556

1,555

1,560

1,560

Outstanding Common Stock Options Having No Dilutive Effect (in shares)

61

-

-

5

1

1

1

1

27

29

66

30

6